Current Report Filing (8-k)
December 03 2018 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 1, 2018
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36167
|
|
26-3931704
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
85 Wells Avenue, 2nd Floor
Newton, Massachusetts
|
|
02459
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
658-0600
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On December 1, 2018, Karyopharm Therapeutics Inc. (the Company) issued a press release announcing the presentation of topline
results from the Phase 2b SADAL study at the American Society of Hematology 2018 Annual Meeting (the ASH Annual Meeting).
On
December 3, 2018, the Company issued a press release announcing the presentation of updated clinical data from the Phase 2b STORM study and from two treatment arms of the Phase 1b/2 STOMP study at the ASH Annual Meeting.
Copies of the press releases are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form
8-K
and are incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
KARYOPHARM THERAPEUTICS INC.
|
|
|
|
|
Date: December 3, 2018
|
|
|
|
By:
|
|
/s/ Christopher B. Primiano
|
|
|
|
|
|
|
Christopher B. Primiano
|
|
|
|
|
|
|
Executive Vice President, Chief Business Officer, General Counsel and Secretary
|
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024